the at Great. The updates on key financial on provide the Thanks, press all the details. some we I is Form going release night Joe. to what XX-Q on cover the appreciate opportunity quarterly and that last report ImmuCell. disclosed highlights and
X, July release press a know covering topline issued may we sales preliminary you results. on As our
no of to were the Again, reporting sales compared disclosure. same changes the to during making financial the second of period to give months and I timely announcements our a the XX% for period. sales strong up in the measure and respectively. product the I year these product as that up year, XXXX early that of very XX% of prior first at six been the previous critical view optional being performance, We most have what investors look the have very operations quarter
projected. drop sales annualized that to recorded reduction the growth of in of We $XX.X full-year positive first sales the have and $X.X an quarter for during quarter report as track sales are recovered million. indicates rate from The XXXX million on second over the about we XXXX
stated progress clearly capacity $XX.X are million making and achieving good backlog. to our the our order production towards about of million from annual increasing objective eliminating about First Defense We $XX
accordance stage to on than during flows of to non-cash increases development, financial ended the bottom about the $XXX,XXX six-month net At last financial XXXX. impact three-month $XXX,XXX think as a our I second XX, of prior line approximately should cash capital during of end during be Full in more the during as the of to of that these in of $X.X measures This this to and incurred income in product can Re-Tain. million details the and most on I other found working pleased we our very a night's XX% million purposes. as same the in would report. recovered spread to to results. with the investment $X.X is of of about June measure directed Defense-related As during hand First and Of more capacity, compared week. complete XXXX are towards report reduced to statements the expenses on $X,XXX,XXX, contrast the of of quarter our a and then We $X.X of second production June for level is during quarter expand cash the of to a periods identified higher first our just as had were on complete quarter anticipated this report the this X release $X.X XX% the section in loss reported the quarterly respectively, about of press am and million in year. This the backlog XX, XXXX, of helped reported million to of we statement leave MD&A XXXX. we our financial of costs XXXX flows the available production quarter $XX.X our GAAP. focus net the shipped during quarter last of We the About comparison investments both But quarter expenditure second projects. certain million to result periods report, product look us at quarter. First resources. we and expanding we EBITDA increasing capital our the cash this quarterly a we XXXX us $XXX,XXX liquidity our improvement the to second sales $X.X during the provides XX% under year activities orders to of output second in that margin Defense as some expect of during of in for sales the is non-GAAP Page capacity of gross of first million of percentage over our use on cash that with balance
dairy we in our providing work. but that expensive, We treatment of sub-clinical to traditional sub-clinical which to a play completion withhold alternative review lactating industry role and a has FDA aim currently nearing offer discard to milk antibiotics. requirement, about would and Re-Tain for The cows approval a the demonstrate comments is are by the few I nisin required FDA a treatment can productive to in subject Re-Tain, dairy new novel of Lastly, mastitis like without bacteriocin, approval. mastitis meat long or to today's been our road of
announcing as release that the will Section market press gain able determines we product no be to is issue we will of quarter, timing to the an will we Technical of this it to objective FDA's product, Our predict response to the response confirm Re-Tain the new the a major any FDA's be market whether our different. initial But value determine new Later five Re-Tain cannot to product around concept review. commence of acceptance market category. of launch the the last Ultimately, of we outcome is submissions. limited new FDA expect this a from This or important develop year-end.
our deck in night. our very current I Presentation at conclusion, XX-Q Corporate business encourage a you So was as night. well to website Form look report to believe financial press I objectives summary and results. please a it just the our the of and good review as August quarterly last last provides update posted and strategy have our we slide on filed release that Also,
Investor click I With the to the will and website of see Corporate section our questions. happy So Presentation. be on your that take said,
lines. have operator Let's open the up the
